Zacks Investment Research
04 Nov 2026, 23:51 UTC · 2h ago
Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates
Impact · against what's priced in
Caris Life Sciences showed strong top-line growth and a beat on both revenue and earnings estimates for Q3 2026. While the earnings beat was significant in percentage terms, the year-over-year EPS decline suggests some margin pressure despite the revenue growth.
- CAI+0.40
No priced-in read yet
- In context
The company reported a 26.9% year-over-year revenue increase to $275.36 million and an adjusted EPS of $0.05, beating consensus estimates for both metrics.
Read from the article alone
Search tags
